论文部分内容阅读
目的 分析肺癌患者组织样品中p16基因启动子区域异常甲基化的改变情况 ,评价该指标作为辅助临床诊断的分子标记物的价值。方法 运用甲基化特异性PCR技术 ,检测 5 1例原发性肺癌患者的肿瘤组织、外周血血浆和痰标本中p16基因启动子区域的异常甲基化改变。结果 在 4 3例肿瘤组织、36例血浆和 39例痰标本中检测到了p16基因异常甲基化。凡在肿瘤组织检出p16基因甲基化阳性的病例 ,其血浆和 (或 )痰标本也为阳性 ;而肿瘤组织p16基因甲基化阴性的病例 ,其血浆和痰标本也为阴性。将血浆和痰标本的p16甲基化分析与痰细胞学检查相结合 ,可以发现 92 .2 %的肺癌病例。结论 利用半巢式甲基化特异性PCR进行的血浆和痰标本p16基因甲基化分析 ,有可能成为辅助肺癌诊断的分子生物学指标。
Objective To analyze the abnormal methylation of p16 gene promoter in lung cancer tissue samples and to evaluate its value as a molecular marker for clinical diagnosis. Methods Methylation-specific PCR was used to detect the aberrant methylation of p16 gene promoter region in tumor tissue, peripheral blood plasma and sputum in 51 patients with primary lung cancer. Results Abnormal methylation of p16 gene was detected in 43 tumor samples, 36 plasma samples and 39 sputum samples. Plasma and / or sputum samples were also positive in cases where methylation of the p16 gene was detected in the tumor tissue, and negative in the plasma and sputum specimens of the methylation-negative p16 gene in the tumor tissue. A combination of sputum cytology and p16 methylation analysis of plasma and sputum samples revealed 92.2% of lung cancer cases. Conclusion Methylation analysis of p16 gene in plasma and sputum using semi-nested methylation-specific PCR may become a molecular biological indicator for diagnosis of lung cancer.